Martec receives marketing approval for diclofenac sodium delayed-release tablets

Drug Store News, May 17, 1999

Martec Pharmaceuticals, the U.S. distributor of products manufactured by Martec Scientific, Inc., ratiopharm GmbH of Ulm, Germany, and Mepha, Ltd., has received marketing clearance from the Food and Drug Administration for diclofenac sodium delayed-release tablets 50 mg and 75 mg. Diclofenac sodium delayed-release tablets are the generic equivalent to Novartis' Voltaren.

The product is in addition to Mzartec's Sucalfate tablets, 1 gm (equivalent to Hoechst Marion Roussel's Carafate), Athenolol and Chlorthalidone tablets, 50/25 mg and 100/25 mg (equivalent to Zeneca's Tenoretic) and Pindolol tablets, 5 mg and 10 mg (equivalent to Novartis' Visken), which were introduced into the market in 1998.

Martec has also filed ANDAs for Pentoxifylline 400 mg tablets (equivalent to Hoechst Marion Roussel's Trental) and Nifedipine XL 30 mg, 60 mg and 90 mg tablets (equivalent to Pfizer's Procardia XL), which are under review at the FDA.